Emergent BioSolutions (EBS) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Emergent BioSolutions Starts Enrollment in Africa or CDC-led MPox Study
TipRanksJan 16 08:05 ET
Express News | Emergent BioSolutions Inc - First Interim Analysis of Mosa Trial Expected by End of Q1 2025
ReutersJan 16 08:01 ET
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
GlobeNewswireJan 16 08:00 ET
Express News | Enrollment Starts in Africa Cdc-Led Mpox Therapeutic Study (Mosa)
ReutersJan 16 08:00 ET
Emergent BioSolutions Outlines Growth at J.P. Morgan Conference
TipRanksJan 15 16:17 ET
Government Contract Update: $17M Payment to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Quiver QuantitativeJan 15 14:52 ET

Comments

Jaguar8

Jan 14 21:45

🔴 Watchlist JANUARY 15,2025, Wednesday. NFA. I won’t be around tomorrow morning.

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...

88

27

3

Jaguar8

Jan 14 06:36

NEWS

$Emergent BioSolutions (EBS.US)$
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Emergent BioSolutions (NYSE: EBS) has secured exclusive commercial rights to KLOXXADO® (naloxone HCl) Nasal Spray in the U.S. and Canada from Hikma Pharmaceuticals through a six-year agreement. This 8 mg naloxone product complements EBS's existing NARCAN® Nasal Spray 4 mg, expanding their portfolio of opioid overdose emergency treatments.
...

Trytosaveabit

Jan 14 06:34

News

$Emergent BioSolutions (EBS.US)$ Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
2 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent's ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in need
Focus remains on increasing access, ra...

1

Jaguar8

Dec 16, 2024 22:18

🟢Watchlist TUESDAY 12/17… quite busy. Squeezing in. NFA

$Tenaya Therapeutics (TNYA.US)$ Trial data on hypertrophic cardiomyopathy (HCM) at 8AM ET. Large float. SI 25.47%. COH $129.9M good for 16.2 months
$Biomea Fusion (BMEA.US)$ Covalent III Trial regarding Type 2 Diabetes mellitus out tomorrow 8AM ET. SI 44.16%. COH $62.4M good for 6.2 months
$Sidus Space (SIDU.US)$ Satellite launch Friday. May continue until launch. Low float. 0 shares LTB.COH $4.8M good for 4.2 months✅
$Maison Solutions (MSS.US)$ PR AH 12/...

40

3

11

Jaguar8

Dec 16, 2024 07:12

NEWS

$Emergent BioSolutions (EBS.US)$
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...

EBS Emergent BioSolutions

Trade Overview

Capital Trend

News

Comments

Trending Stocks